Mostrar el registro sencillo del documento

dc.creatorBogani, Giorgio
dc.creatorDitto, Antonino
dc.creatorBosio, Sara
dc.creatorBrusadelli, Claudia
dc.creatorRaspagliesi, Francesco
dc.date.accessioned2020-07-22T15:50:05Z
dc.date.available2020-07-22T15:50:05Z
dc.date.created2020
dc.identifier.issn0090-8258spa
dc.identifier.otherhttps://doi.org/10.1016/j.ygyno.2020.06.161spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/10938
dc.description.abstractObjective. SARS-CoV-2 pandemic is continuing to spread. There are growing concerns on the impact of COVID19 in cancer patients. Several papers reporting recommendations and guidelines are published. But few data on cancer patients affected by COVID-19 are available. Methods. This is a retrospective study including all consecutive patients affected by gynecological cancer who developed COVID-19. All patients were treated in an academic setting (in Milan, Lombardy, Italy) between February and March 2020. Results. Overall, 355 patients had active treatment during the study period due to newly diagnosed or recurrent gynecological disease. Among those, 19 (5.3%) patients affected developed COVID-19. All patients were asymptomatic at the time of COVID-19 detection. Six patients were diagnosed before starting planned treatments; while the remaining 13 were diagnosed for COVID-19 after their started their treatments. Considering the first group of six patients, one patient died due to COVID-19 3 days after the diagnosis; while the other patients recovered from COVID-19 after a median of three weeks. The latter group of 13 patients (treatments started) included five patients who underwent surgery and eight patients who underwent chemotherapy. Focusing on five patients who were diagnosed after surgery, we observed that two patients died during postoperative course, while in other two cases prolonged hospitalization was needed. One patient had no issues. Chemotherapy was delayed for the remaining patents without sequelae. Conclusions. Our report highlights that COVID-19 impacts the quality of treatments for cancer patients. Mortality rate is high, especially after surgery. More important, patients under active treatment for cancer are at high risk of developing severe evolution of COVID-19. Prioritizing patients journey during COVID-19 is of paramount importance.spa
dc.format.extent4 páginasspa
dc.format.mimetypeimage/jepgspa
dc.publisherScience Directeng
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subjectSARS-CoV-2spa
dc.subjectCancerspa
dc.subjectOncologyspa
dc.titleCancer patients affected by COVID-19: Experience from Milan, Lombardyspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.identifier.doihttps://doi.org/10.1016/j.ygyno.2020.06.161spa


Archivos en el documento

Thumbnail
Thumbnail

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento